Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.
Epailly E, Albanell J, Andreassen A, Bara C, Campistol JM, Delgado JF, Eisen H, Fiane AE, Mohacsi P, Schubert S, Sebbag L, Turazza FM, Valantine H, Zuckermann A, Potena L. Epailly E, et al. Among authors: albanell j. Clin Transplant. 2011 Sep-Oct;25(5):E475-86. doi: 10.1111/j.1399-0012.2011.01476.x. Epub 2011 May 18. Clin Transplant. 2011. PMID: 21592231 Review.
Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR. Campistol JM, et al. Among authors: albanell j. Nephrol Dial Transplant. 2007 May;22 Suppl 1:i36-41. doi: 10.1093/ndt/gfm090. Nephrol Dial Transplant. 2007. PMID: 17456617 Review.
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
Taus Á, Camacho L, Rocha P, Hernández A, Longarón R, Clavé S, Fernández-Ibarrondo L, Salido M, Hardy-Werbin M, Fernández-Rodríguez C, Albanell J, Bellosillo B, Arriola E. Taus Á, et al. Among authors: albanell j. Arch Bronconeumol (Engl Ed). 2021 May;57(5):323-329. doi: 10.1016/j.arbres.2020.01.023. Epub 2020 Apr 3. Arch Bronconeumol (Engl Ed). 2021. PMID: 32253118 English, Spanish.
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study.
Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J. Rojo F, et al. Among authors: albanell j. Clin Cancer Res. 2010 Apr 15;16(8):2474-82. doi: 10.1158/1078-0432.CCR-09-3042. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371675 Clinical Trial.
Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. Rojo F, et al. Among authors: albanell j. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24347552
263 results